Dr. Dupré is a neurologist at the CHU de Québec-Laval University, a Full Professor in the Department of Medicine of the School of Medicine (Laval University), and the Director of the Neuromuscular and Neurogenetic Disease Clinic of the CHU de Québec – Université Laval.
Dr. Dupré completed his medical training at McGill University and his residency in neurology at Laval University. He completed his postdoctoral training at the Montreal Neurological Hospital and Institute and at Harvard University. In 2007, he discovered a gene (syne-1) implicated in a new form of hereditary ataxia that has since been highly recognized internationally. Dr. Dupré also played an important role in the discovery of the involvement of the TARDBP in the etiology of amyotrophic lateral sclerosis. He is now involved in several provincial, national, and international networks that contribute to the discovery of genes involved in neurological diseases. He has generated more than 100 original publications. Dr. Dupré’s remarkable achievements have earned him several awards, including the 2015 Quebec Society of Muscular Dystrophy Award – ALS component – related to his involvement in the Clinic for Neuromuscular and Neurogenetic Diseases.
The research component of the clinic has grown significantly in recent years, with the creation of the Québec Parkinson Network (rpq-qpn.ca). The network connects clinicians with basic science researchers in the field, giving access to a registry of nearly 1000 patients. In addition to his clinical program, Dr. Dupré is involved in research projects linking clinical and basic research. This is done in collaboration with Dr. François Gros-Louis, of the LOEX research center at CHU de Québec – Laval University. One of these projects aims to discover biomarkers of amyotrophic lateral sclerosis in the skin. Another important project Dr. Dupré takes part in focuses on the development of a reconstructed skin model to study neurofibromatosis. Finally, Dr. Dupré is actively collaborating with Dr. Gros-Louis to identify pathogenic mechanisms of intracranial aneurysms in the Inuit and French-Canadian populations and to develop in vitro models of the disease. This project has just been funded by CIHR for a duration of 5 years.
Département des sciences neurologiques
Canada G1J 1Z4
- [ULaval Nouvelles] COVID-19: des effets persistants sur le goût et l’odorat chez le tiers des personnes infectées 2022-05-30
- [Le Soleil] Premières lignes directrices canadiennes pour la prise en charge de la SLA 2020-11-18
- [Radio-Canada] COVID-19 et perte d’odorat sous la loupe des chercheurs du CHU de Québec 2020-09-01
- Blais, MathieuEmployeeHôpital de l'Enfant-Jésus+1 418-990-8255, extension email@example.comMATHIEU.BLAIS@crchudequebec.ulaval.ca
1401 18e Rue
LOEX / CMDGT
Ville de Québec, QC
Canada G1J 1Z4
- Buteau-Verret, OlivierInternolivier.firstname.lastname@example.org
- Caron, VickyEmployee+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
- Déry, CatherineMaster firstname.lastname@example.org
- Tremblay-Desbiens, ClémenceEmployeeclemence.email@example.com
- Trudel, PierreEmployeepierre.firstname.lastname@example.org
- Vézina, AlexandreMaster email@example.com
Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future PerspectivesJournal Article
CNS Neurol Disord Drug Targets, 2022.
Recessive cerebellar and afferent ataxias - clinical challenges and future directionsJournal Article
Nat Rev Neurol, 18 (5), 2022.
Goal management training and psychoeducation / mindfulness for treatment of executive dysfunction in Parkinson's disease: A feasibility pilot trialJournal Article
PLoS One, 17 (2), 2022.
Environmental risk factors for amyotrophic lateral sclerosis: a case-control study in Canada and FranceJournal Article
Amyotroph Lateral Scler Frontotemporal Degener, 23 (7-8), 2022.
Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysisJournal Article
JAMA Neurol, 79 (2), 2022.
Moyamoya Disease Susceptibility Gene RNF213 Regulates Endothelial Barrier FunctionJournal Article
Stroke, 53 (4), 2022.
Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosisJournal Article
Hum Brain Mapp, 43 (5), 2022.
Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practicesJournal Article
Amyotroph Lateral Scler Frontotemporal Degener, 23 (3-4), 2022.
Altered Theory of Mind in Parkinson's Disease and Impact on Caregivers: A Pilot StudyJournal Article
Can J Neurol Sci, 49 (3), 2022.
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experienceJournal Article
Parkinsonism Relat Disord, 91 , 2021.
- Comprehensive Analysis Platform To Understand,Remedy and Eliminate ALS, from 2021-01-01 to 2025-03-31
- Creating an Open Science Repository of ARCA1 iPSCs, from 2021-05-31 to 2023-05-31
- Développement d’une approche en santé durable pour la recherche sur le Parkinson et les troubles associés, from 2022-04-29 to 2023-04-30
- Reseau Parkinson Québec_RPQ / Quebec Parkinson, from 2022-04-01 to 2023-03-31
- The Canadian Parkinson Network, from 2018-10-01 to 2023-09-30
Recently finished projects
- Capture ALS - Time Frame, from 2021-10-28 to 2022-10-27
- Creating an Open Science Repository of ARSACS hiPSCs, from 2020-10-23 to 2021-10-22
- Crosstalk between immune response and metabolic signaling: targeting leptin/AMPK axis to restore metabolic homeostasis in ALS, from 2021-02-01 to 2023-01-31
- Pathogenic Pathways and in-vitro modelization of Intracranial Aneurysms in populations of Inuit and French Canadian descent, from 2017-04-01 to 2022-03-31
- Projet 2016-2792 pour les activités de recrutement, from 2019-04-04 to 2021-03-31